Article Text

Download PDFPDF
Highlights from the literature

Statistics from

Not all children who fail to respond to induction chemotherapy for acute lymphoblastic leukaemia (ALL) have a gloomy prognosis. Data from 14 cooperative study groups in Europe, North America, and Asia (New England Journal of Medicine 2012;366:1371–81; see also editorial, ibid: 1445–6) have shown that certain features indicate a better prognosis and probable response to chemotherapy without stem-cell transplantation. Of a total of 44017 children with ALL treated between 1985 and 2000, 1041 (2.4%) had induction failure. They often presented with high-risk features and after an average follow-up of 8.3 years the overall estimated 10-year survival rate was 32%. A poor prognosis was associated with age >10 years, T-cell leukaemia, 11q23 rearrangement, and 25% or more blasts in bone marrow at the end of induction therapy. Features associated with a better prognosis, however, included age 1–5 years and high hyperdiploidy (modal chromosome number >50) in children with precursor B-cell leukaemia. Among such children with no adverse genetic features the estimated 10-year survival was 72% with chemotherapy alone. About 25% of patients with cytogenetic data were in this group. Children with T-cell leukaemia and induction failure will probably continue to be treated with allogeneic stem-cell transplantation. Children with B-cell leukaemia and other favourable features may do better with chemotherapy alone.

Evidence including registry based cohort studies and meta-analyses has linked reproductive technologies such as in vitro …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.